Kinarus receives 7 Million CHF Grant from the Swiss Federal Funding Programme for COVID-19 Medicines
Dec 13, 2021 4:08 PM
Kinarus AG has been awarded a grant from the Swiss Federal Funding Programme for the development of COVID-19 Medicines
These funds will support lead drug candidate KIN001, as a potential new therapy for all severities of COVID-19
The KIN001 program consists of two Phase 2 clinical studies; the KINETIC trial in hospitalized COVID-19 patients, and an outpatient trial in mild-moderate cases
Basel, Switzerland, December 13, 2021. Kinarus AG, a Swiss clinical-stage biopharmaceutical company announced today that it has been awarded a grant in the amount of 7 million CHF from the Swiss Federal Funding Programme for COVID-19 Medicines. Kinarus is conducting two clinical studies of KIN001 in COVID-19; KINETIC, a randomized placebo-controlled trial of KIN001 in hospitalized COVID-19 patients, and KIN001-204, a randomized placebo-controlled trial in COVID-19 patients with mild-moderate symptoms.
The funds from the COVID-19 medicines program will enable Kinarus to rapidly advance both clinical trials. In preclinical tests, KIN001 has shown potent antiviral, antifibrotic and anti-inflammatory activity. Based on these data, Kinarus’ lead drug candidate has the potential to be an effective therapy for all severities of COVID-19 and variants of interest. The recent, rapid emergence of the omicron variant of SARS-CoV-2 illustrates the continuing need for new therapies for COVID-19.
“This grant award is an exceptional validation of our COVID-19 program at Kinarus. We believe that KIN001 has the potential to be an effective treatment option in the fight against COVID-19,” said Matthew Wright, Ph.D., Chief Operating Officer and Head of Research. “The speed with which we have advanced this program reflects the high promise of KIN001. The emergence of the delta variant and, more recently omicron, illustrate the ongoing need for broadly available oral treatment options. The Kinarus team is committed to rapidly develop therapies for patients with COVID-19.”
KIN001 is an orally administered combination of the p38 MAPK inhibitor pamapimod and the PPAR gamma agonist pioglitazone. Preclinical data have shown that KIN001 has potent antiviral activity against SARS-CoV-2 and emerging variants of interest. KIN001 has also been shown to significantly reduce lung inflammation and fibrosis by blocking multiple cytokines and inflammatory proteins. In April 2021, Kinarus enrolled the first patient in the KINETIC Phase 2 clinical trial of KIN001 in hospitalized COVID-19 patients.
About the Swiss Federal Funding Programme for COVID-19 Medicines
The Federal Funding Programme for COVID-19 Medicines aims to support innovative pharmaceutical projects that make a contribution to the rapid supply of COVID-19 medicines for the Swiss population. On the 30th of June, 2021, the Swiss Federal Council mandated the Federal Office of Public Health to implement this programme, with the support of Innosuisse. The Kinarus application was one of four projects that were judged positively.
Kinarus AG is a Swiss clinical-stage biopharmaceutical company focused on bringing differentiated treatments to patients suffering from viral, respiratory, or ophthalmic diseases. Kinarus’ differentiated therapeutic candidate, KIN001, has broad potential to transform numerous therapeutic areas. The company has patents covering the application of KIN001 in multiple indications. Kinarus is actively enrolling patients in the KINETIC Phase 2 clinical trial of KIN001 in hospitalized COVID-19 patients.
For more information, please visit the company’s website at www.kinarus.com.
Tel: +41 61 633 2971
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Kinarus AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions.